Richard Vosser
Stock Analyst at J.P. Morgan
(3.51)
# 2,274
Out of 5,005 analysts
1054
Total ratings
50.1%
Success rate
2.4%
Average return
Main Sectors:
Stocks Rated by Richard Vosser
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LON: AZN AstraZeneca PLC | Maintained: Buy | 16,000p | 12,492p | +28.08% | 41 | Sep 29, 2026 | |
| ETR: SRT3 Sartorius Aktiengesellschaft | Reiterated: Buy | €295.00 | €263.50 | +11.95% | 76 | Sep 28, 2026 | |
| EPA: DIM Sartorius Stedim Biotech S.A. | Reiterated: Buy | €260.00 | €216.60 | +20.04% | 30 | Sep 28, 2026 | |
| SWX: NOVN Novartis AG | Reiterated: Buy | n/a | $121.40 | - | 121 | Sep 7, 2026 | |
| ETR: BAYN Bayer Aktiengesellschaft | Reiterated: Buy | €61.00 | €50.80 | +20.08% | 147 | Sep 3, 2026 | |
| EPA: SAN Sanofi | Reiterated: Hold | €95.00 | €72.00 | +31.94% | 166 | Jul 31, 2026 | |
| EPA: IPN Ipsen S.A. | Reiterated: Hold | n/a | $143.50 | - | 16 | Jun 29, 2026 | |
| ETR: MRK Merck KGaA | Reiterated: Buy | €150.00 | €138.45 | +8.34% | 145 | Jun 1, 2026 | |
| SWX: ROP Roche Holding AG | Reiterated: Hold | CHF 325.00 | CHF 355.40 | -8.55% | 191 | May 1, 2026 | |
| LON: GSK GSK plc | Reiterated: Sell | n/a | $1,860.00 | - | 7 | Dec 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $925 → $1,100 | $972.25 | +13.14% | 2 | Dec 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | CHF 3.50 → CHF 3.00 | CHF 3.30 | -9.09% | 15 | Dec 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $38.71 | - | 21 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $146.88 | - | 4 | Nov 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $4.5 → $4 | $3.86 | n/a | 8 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | €250.00 → €260.00 | €207.00 | n/a | 17 | Jul 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | CHF 645.00 → CHF 650.00 | CHF 584.20 | n/a | 15 | Dec 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | €3.00 → €3.50 | €0.75 | n/a | 6 | Dec 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $54 → $39 | $14.46 | n/a | 7 | Dec 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | €43.62 | €53.15 | n/a | 1 | Jan 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | 3,000p | 1,592p | n/a | 7 | Sep 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $176 | $36.39 | n/a | 1 | Mar 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $53.37 | n/a | 3 | Dec 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $142 | $121.15 | n/a | 1 | Jul 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $205 → $200 | $29.84 | n/a | 2 | Mar 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | €185.00 | €25.98 | n/a | 1 | Jan 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $35.36 | n/a | 1 | Jan 2, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Hold | n/a | $41.18 | n/a | 1 | Apr 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $22 | $7.41 | n/a | 1 | Jan 4, 2017 |
AstraZeneca PLC
Sep 29, 2026
Maintained: Buy
Price Target: 16,000p
Current: 12,492p
Upside: +28.08%
Sartorius Aktiengesellschaft
Sep 28, 2026
Reiterated: Buy
Price Target: €295.00
Current: €263.50
Upside: +11.95%
Sartorius Stedim Biotech S.A.
Sep 28, 2026
Reiterated: Buy
Price Target: €260.00
Current: €216.60
Upside: +20.04%
Novartis AG
Sep 7, 2026
Reiterated: Buy
Price Target: n/a
Current: $121.40
Upside: -
Bayer Aktiengesellschaft
Sep 3, 2026
Reiterated: Buy
Price Target: €61.00
Current: €50.80
Upside: +20.08%
Sanofi
Jul 31, 2026
Reiterated: Hold
Price Target: €95.00
Current: €72.00
Upside: +31.94%
Ipsen S.A.
Jun 29, 2026
Reiterated: Hold
Price Target: n/a
Current: $143.50
Upside: -
Merck KGaA
Jun 1, 2026
Reiterated: Buy
Price Target: €150.00
Current: €138.45
Upside: +8.34%
Roche Holding AG
May 1, 2026
Reiterated: Hold
Price Target: CHF 325.00
Current: CHF 355.40
Upside: -8.55%
GSK plc
Dec 23, 2025
Reiterated: Sell
Price Target: n/a
Current: $1,860.00
Upside: -
Dec 8, 2025
Reiterated: Buy
Price Target: $925 → $1,100
Current: $972.25
Upside: +13.14%
Dec 8, 2025
Reiterated: Hold
Price Target: CHF 3.50 → CHF 3.00
Current: CHF 3.30
Upside: -9.09%
Nov 24, 2025
Reiterated: Buy
Price Target: n/a
Current: $38.71
Upside: -
Nov 20, 2025
Reiterated: Hold
Price Target: n/a
Current: $146.88
Upside: -
Sep 3, 2025
Reiterated: Hold
Price Target: $4.5 → $4
Current: $3.86
Upside: n/a
Jul 22, 2025
Reiterated: Buy
Price Target: €250.00 → €260.00
Current: €207.00
Upside: n/a
Dec 3, 2024
Reiterated: Buy
Price Target: CHF 645.00 → CHF 650.00
Current: CHF 584.20
Upside: n/a
Dec 3, 2024
Reiterated: Hold
Price Target: €3.00 → €3.50
Current: €0.75
Upside: n/a
Dec 5, 2023
Reiterated: Hold
Price Target: $54 → $39
Current: $14.46
Upside: n/a
Jan 3, 2023
Upgraded: Buy
Price Target: €43.62
Current: €53.15
Upside: n/a
Sep 27, 2021
Reiterated: Buy
Price Target: 3,000p
Current: 1,592p
Upside: n/a
Mar 18, 2021
Reiterated: Buy
Price Target: $176
Current: $36.39
Upside: n/a
Dec 21, 2020
Reiterated: Buy
Price Target: n/a
Current: $53.37
Upside: n/a
Jul 28, 2020
Reiterated: Buy
Price Target: $142
Current: $121.15
Upside: n/a
Mar 2, 2020
Reiterated: Hold
Price Target: $205 → $200
Current: $29.84
Upside: n/a
Jan 6, 2020
Downgraded: Hold
Price Target: €185.00
Current: €25.98
Upside: n/a
Jan 2, 2019
Downgraded: Hold
Price Target: n/a
Current: $35.36
Upside: n/a
Apr 11, 2017
Upgraded: Hold
Price Target: n/a
Current: $41.18
Upside: n/a
Jan 4, 2017
Upgraded: Buy
Price Target: $22
Current: $7.41
Upside: n/a